Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Specimen Handling 483pembrolizumab 456Magnetic Resonance Spectroscopy 420Carboplatin 327Cyclophosphamide 315Biopsy 274Cisplatin 270Radiotherapy 244Paclitaxel 229Gemcitabine 225Bevacizumab 214Nivolumab 189fludarabine 184venetoclax 174Drug Therapy 171Dexamethasone 158Blood Specimen Collection 158Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 145Docetaxel 144Radiosurgery 137Standard of Care 136Rituximab 125Pemetrexed 117durvalumab 114atezolizumab 110Leucovorin 110Radiation 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cytochrome P-450 CYP1A2 × 1 year × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡